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Abstract
Background
Endometriosis is defined by the presence of endometrial-like tissue (lesions) outside the
uterus, commonly on the pelvic peritoneum. It affects 6–10% of women and is associated
with debilitating pelvic pain. Current management options are often unsatisfactory. Omega-
3 polyunsaturated fatty acids (O-PUFA) have the potential to reduce the painful symptoms
associated with endometriosis, reduce lesion size, preserve the patient’s ability to conceive,
and have minimal side effects. We performed a two-arm, parallel double-blinded rando-
mised controlled trial to inform the planning of a future multicentre randomised controlled
trial to evaluate the efficacy of O-PUFA for endometriosis-associated pain.
Objectives
The primary objectives of the trial were to assess recruitment and retention rates. The sec-
ondary objectives were to determine the acceptability to women of the proposed methods of
recruitment, randomisation, treatments and questionnaires, to estimate the variability in the
proposed primary endpoints to inform the sample size calculation and to refine the research
methodology for the future definitive trial.
Methods
We recruited women with endometriosis from June 2016 to June 2017 and randomised
them to eight weeks of treatment with O-PUFA or olive oil. Pain scores and quality of life
questionnaires were collected at baseline and eight weeks. We calculated the proportion of
eligible women randomised, and of randomised participants who were followed up to eight
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Results
The proportion of eligible participants who were randomised was 45.2% (33/73) and 81.8%
(27/33) completed the study. The majority of participants described their overall trial experi-
ence favourably and there were no adverse events in either group.
Conclusion
Our pilot trial supports the feasibility of a future larger trial to definitively evaluate the efficacy
of O-PUFA for endometriosis-associated pain.
Trial registration
The trial was registered on the ISRCTN registry (registration number ISRCTN44202346).
Introduction
Endometriosis is a chronic oestrogen-dependent inflammatory condition that affects around
176 million women worldwide [1, 2]. It is defined by the presence of endometrial-like tissue
(‘lesions’) outside the uterus, and is associated with debilitating pelvic pain and infertility. It is
a complex, heterogeneous disorder, poorly understood, and the aetiology remains unknown.
Management options for endometriosis-associated pain include surgical removal of lesions
and medical treatment with ovarian suppressive drugs [3, 4]. However, the recurrence of endo-
metriosis-associated pain is up to 50% within five years following surgery [5], and drug treat-
ments are contraceptive and/or have menopausal-like side-effects and may not fully resolve
pain [6].
Oral Omega-3 polyunsaturated fatty acids (O-PUFA; eicosapentaenoic acid [EPA] and
docosahexaenoic acid [DHA]) [7] have potential to (i) reduce the painful symptoms associated
with the condition, (ii) reduce lesion size, (iii) preserve the patients’ ability to conceive while
on medication, and (iv) have no, or limited, side effects. The Food and Drug Association
(FDA) has approved a “qualified health claim” for O-PUFA for lowering plasma triglycerides
and approved several high dose formulations as drugs [8]. However, whilst there are mechanis-
tic data to support a lipid-mediated mechanism for endometriosis [9], there is only anecdotal
evidence of benefit from O-PUFA and no evidence from randomised controlled trials in this
population.
O-PUFAs play a role in the regulation of prostaglandins and cytokines, factors critical to
endometriosis, by competing with Omega-6 PUFA to produce anti-inflammatory lipid media-
tors [6]. Intake of food with a high content of O-PUFA has been shown to have an anti-inflam-
matory effect in conditions such as atherosclerosis [10]. Importantly, it has been shown that
O-PUFAs can serve as substrates for formation of a wide range of mediators implicated in res-
olution of inflammation [11–15].
In a rat model of endometriosis, O-PUFA reduced lesion size and local prostaglandin and
cytokine production [15]. Administration of D-series resolvins (DHA metabolites) also
reduced vaginal hyperalgesia [14]. In an endometriosis model using Fat-1 mice, in which
Omega-6 can be converted to O-PUFA, the number of induced lesions were significantly less
Omega-3 polyunsaturated fatty acids for the treatment of women with endometriosis
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in Fat-1 mice compared to controls [13] and inflammatory mediators such as IL-6 and Cox-2
levels were reduced [12]. In in-vitro studies, using endometrium from women with endometri-
osis, it has been shown that O-PUFA has a suppressive effect on endometrial cell survival [11],
corroborating the animal data.
A large, prospective cohort study investigated dietary exposure and endometriosis risk in
women, and concluded that increasing O-PUFA intake might reduce the risk of endometriosis
[16]. A dietary modification and supplementation trial, which included O-PUFA, reduced
pain scores in women with endometriosis [17]. A low ratio of O-PUFA to Omega-6 PUFA
intake is also reported to correlate with painful menstruation in women with endometriosis
[18], with fish oil supplementation significantly reducing pain scores in adolescents with men-
strual pain [19].
We believe that it is important to determine the true value of O-PUFA for the control of, or
potential elimination of, endometriosis-associated pain. A definitive evaluation of the efficacy
of O-PUFA in the management of endometriosis-associated pain will require a large, multi-
centre randomised controlled trial (RCT). We therefore performed a two-arm, parallel dou-
ble-blind randomised controlled pilot trial to inform the planning of a future multicentre RCT
to evaluate the efficacy of O-PUFA for endometriosis-associated pain.
Materials and methods
Study design
We performed a two-arm, parallel, double-blind randomised controlled pilot trial. Women
with a surgical diagnosis of endometriosis and associated pelvic pain were recruited from
gynaecology outpatient clinics, gynaecology wards and day surgery units within the Royal
Infirmary of Edinburgh over a 12-month period from 30th June 2016 to 16th March 2017. Data
Collection was completed on 7th June 2017 (Fig 1). The trial protocol has been published
online [20]. Ethical approval was obtained from the Scotland A Research Ethics Committee
(LREC 16/SS/0010) on 02/02/2016 and informed written consent was obtained from all
participants.
Inclusion criteria
Women were eligible for inclusion if they were as follows:
• Aged between 18 and 50 years.
• Pelvic pain of> 3 months
• Pain located within the true pelvis (between or below the iliac crests)[21]
• Endometriosis diagnosed macroscopically by laparoscopy (performed at least two weeks
prior to enrolment)
• A numerical rating average ‘worst’ pain score (NRS) of greater than or equal (�) to four (see
below for details).
Exclusion criteria
Women were excluded if they had one or more of the following:
• Unable to take/allergic to fish/O-PUFA/peanuts/soyabean
• Insulin-dependent diabetes
Omega-3 polyunsaturated fatty acids for the treatment of women with endometriosis
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• Pregnancy
• Taking anticoagulants
• Breast feeding
• Unable to give informed consent
Sample size
The aim of this pilot was to establish feasibility of a future trial—it was therefore designed pri-
marily to explore recruitment and retention rates. To achieve this, the aim was to recruit as
many women as possible over a 12-month period. Based on estimates of the number of eligible
patients, we postulated that we would recruit four to five patients per month (and recruit 40
patients in 12 months). Based on a recruitment rate of 50%, we estimated that 40 participants
would give a 95% confidence interval (CI) of 39–61% (using the Normal approximation since
the denominator is�50).
Screening
Eligibility for randomisation was based on the worst of four weekly numerical rating scale (0–
10; NRS) pain scores collected by text messaging (‘run-in phase’). A score of four out of ten in
two or more weeks was required. Texts were sent to the woman’s mobile phone, asking about
average and worst pain, respectively, and the woman was asked to reply to the text message
with her pain score, rating it from 0 for no pain at all, to 10 being worst pain imaginable. To
capture known cyclicity in pain, the texts were sent once per week during the eligibility phase
Fig 1. Trial consort diagram.
https://doi.org/10.1371/journal.pone.0227695.g001
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(weeks ‘minus four’ to ‘minus one’). If a woman had an NRS of greater than or equal to� four
in two or more of the pre-randomisation run-in weeks of the study, she was considered to be
eligible for randomisation.
Randomisation
The randomisation scheme was generated using tables, drawn up by an independent statisti-
cian, with 1:1 allocation ratio using blocks of four and six in a random pattern. The allocated
treatment codes were sealed in consecutively numbered opaque envelopes. When a woman
was randomised into the study, she received the treatment indicated in the next available
envelope.
Interventions
Participants were randomly assigned to the intervention (Omega-3-acid ethyl ester PUFA
filled capsules, one capsule (1000mg) twice a day) or a visually identical comparator (olive oil,
soft gelatin capsules, one capsule twice a day) for eight weeks. The allocated treatments were
taken for eight weeks. O-PUFA capsules have been used clinically in previous trials (post-myo-
cardial infarction and for hypertriglyceridemia) at doses of 1000-4000mg daily (in divided
doses of 1000mg or 2000mg) [7]. However, high dosage (i.e. 4000mg) has been associated with
a moderate increase in post-operative bleeding so we chose to pilot a lower dose and frequency
of one capsule (1000mg) twice a day. We approached the Medicines and Healthcare products
Regulatory Agency (MHRA) for advice regarding the classification of O-PUFA and olive oil.
As both O-PUFA and olive oil capsules are ‘food supplements’, our trial was not deemed a
Clinical Trial of an Investigational Medicinal Product (CTIMP).
Co-primary objectives
Recruitment and retention rates.
Secondary objectives
• Estimation of the variability of responses to inform the primary outcome and sample size of
the future RCT.
• Acceptability of proposed methods of recruitment, randomisation, treatments and
questionnaires.
Questionnaires
Participants were given the questionnaires below (see published protocol for further details
[20]) to complete at baseline and eight weeks. Baseline demographic and clinical characteris-
tics of the participants were also recorded at baseline.
• Brief Pain Inventory (BPI)
• 12-Item Short-Form Health Survey (SF-12)
• Pain Catastrophizing Questionnaire (PCQ)
• Pain DETECTTM
• Sexual Activity Questionnaire (SAQ)
• Brief Fatigue Inventory (BFI)
Omega-3 polyunsaturated fatty acids for the treatment of women with endometriosis
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• General Health Questionnaire-12 (GHQ-12)
• Work and Productivity Impairment
• Questionnaire-specific Health Problem Version 2.0 (WPAI-SHP)
An additional acceptability questionnaire was completed at the end of the study only. This
questionnaire included questions about whether participants believed that they were receiving
O-PUFA or olive oil, the acceptability of the allocated medication/ treatment regimens (and
compliance) and on the acceptability of completing trial-specific procedures including the
questionnaires. All questionnaires were anonymised and self-completed in private.
Treatment diaries
Participants were provided with a treatment diary at the same time as their medication pack
was dispensed. All medications other than the trial treatment taken during the treatment
phase of the study were recorded in a treatment diary. This included prescription and non-
prescription treatments, such as oral analgesics, contraceptives, vitamins, topical preparations
and herbal preparations.
Adverse events
Participants collected information about adverse events in their treatment diaries. They were
also instructed to contact the clinical trial team at any time after consenting to join the trial if
they had an event that requires hospitalisation or an event that resulted in persistent or signifi-
cant disability or incapacity.
Participant log
We kept an anonymised electronic log of women who fulfilled the eligibility criteria, women
who were invited to participate in the study, women who were recruited and women who left
the trial early. Reasons for non-recruitment (e.g. non-eligibility, refusal to participate, adminis-
trative error) were also recorded. We attempted to collect reasons for non-participation from
women who declined to take part after previously providing contact details. During the course
of the study, we attempted to document reasons for withdrawal from the study and loss to fol-
low-up.
Statistical analysis
A statistical analysis plan was agreed with the trial statistician (Dr Linda Williams, University
of Edinburgh) prior to a database lock. Estimates of recruitment and retention were to be cal-
culated with their 95% Confidence Interval (CI). Where the denominator is small (<50), exact
binomial confidence intervals will be calculated. Where the denominator is large the Normal
approximation will be used. Change from baseline for each of the questionnaires and sub-
questions were calculated for each patient, and these changes were compared between treat-
ments using the t-test. Where the change from baseline was not normally distributed, the
change was transformed on the log scale, and this was compared between treatments. All tests
were by intention-to-treat and two-sided, with a 1% level of significance to make some allow-
ance for multiple testing. Only patients with baseline and follow-up at eight weeks were
included. Due to the small sample size, no attempts were made to impute missing data. Statisti-
cal analysis was performed using Microsoft Excel (ME) and SPSS software version 23. The
number and nature of unanswered questions was recorded and explored.
Omega-3 polyunsaturated fatty acids for the treatment of women with endometriosis
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Trial sponsors
The trial was co-sponsored by the University of Edinburgh and NHS Lothian.
Results
Baseline characteristics
Table 1 presents the participants’ characteristics per group. The majority of participants had a
menstrual cycle, more than three-quarters of them had attained a college/university degree
and only one participant was non-Caucasian (Asian). More than half of the participants (57%)
never smoked. Two thirds of them had never been pregnant. 79% of the recruited women had
a diagnosis of superficial peritoneal endometriosis. Less than half of the participants required
contraception and the levonorgestrel- releasing intrauterine system was the most popular
method.
Recruitment and retention rates
The proportion of eligible participants who were randomised over 12 months was 45.2% (33/
73, 95% CI 33.5, 57.3%)) and 81.8% (27/33, 95% CI (64.5, 93.0%)) completed the study. Seven-
teen participants were randomised to receive O-PUFA group and 16 participants were rando-
mised to receive olive oil capsules. Examples of reasons for non-participation included ‘trying
to conceive’, ‘strict vegetarian and will not accept fish oil, want only olive oil’, and ‘already
taken the fish oil without much help’. Six participants were lost to follow-up, three from each
treatment group.
Estimation of variability of responses to inform the primary outcome of
the future definitive trial
Supplementary tables (S1–S8 Tables) summarise the variability in responses to the question-
naires. There was no statistically significant difference in pain scores or quality of life outcomes
in the two treatment groups but there was a trend toward improvement in pelvic pain and
quality of life scores in both treatment arms over the eight week intervention points. For the
secondary outcome measures, estimates of treatment effects were presented with 95% two-
sided CI. P-values were reported from two-sided tests at the 5% significance level, although as
secondary endpoints these were mostly under-powered. A two-sided P-value of� 0.01 was
considered statistically significant.
In order to calculate the required sample size for a future RCT, we assumed that our pri-
mary outcome measure was the BPI severity score. From our results, we estimated a pooled
standard deviation (SD) of 2.08. In order to detect a difference of 1 unit on the BPI scale,
which is approximately a fall of 20% from the baseline mean, with a power of 80% and a signif-
icance level of 5%, we utilised the sample size equation for a difference in continuous data.
This requires at least 69 analysable patients per group. Similarly, if we wished to use the inter-
ference score as the primary or co-primary outcome, the pooled SD is 2.18 and we would
require 76 patients per group. However, we would also need to take loss to follow up into
account (retention), and the recruitment rate in order to estimate the number of patients we
would need to approach in order to achieve sufficient patients to achieve our primary out-
come. A point estimate and 95% CI have been reported for recruitment and retention. As
these figures (69 or 76) refer to the number of evaluable patients required, adjustments for
retention will be made (Fig 2).
Omega-3 polyunsaturated fatty acids for the treatment of women with endometriosis
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Table 1. Baseline characteristics.
O-PUFA Olive Oil Capsules
N % N %
17 51.5 16 48.5
Age Mean 35.43 36.08
Std. Deviation 8.57 9.59
Range 21–48 24–49
BMI (kg/m2) Mean 27.86 23.95 -
Std. Deviation 7.89 4.29
Range 18.3–41.1 16.9–33.4
Highest education received Primary school 0 0 0 0
Secondary school 3 11.1 3 11.1
College/university 11 40.7 10 37
Ethnicity Caucasian 14 51.9 12 44.4
Other (Asian) 0 0 1 4
Smoking Smoker 3 10.7 1 3.6
Ex-smoker 4 14.3 4 14.3
Never smoked 8 28.6 8 28.6
Diet habit Vegetarian 0 0 0 0
Seafood 0 0 0 0
Vegetarian and seafood 2 14.3 2 15.4
Others 12 85.7 11 84.6
Parity None 10 37 8 29.6
1 or more 4 14.8 5 18.5
Periods Yes 11 40.7 4 14.8
No 3 11.1 9 33.3
Pain during periods Yes 11 40.7 7 25.9
No 3 11.1 6 22.2
Pain during intercourse Yes 11 44 9 36
No 3 11.1 4 14.8
Previous gynaecological operations (other than first laparoscopy) >1 4 28.5 7 53.8
>2 3 21.4 3 23
>3 or more 7 50 3 23
Type of endometriosis Superficial peritoneal 10 41.7 9 37.5
Ovarian 1 4.2 1 4.2
Deep 2 8.3 1 4.2
Contraception Patch 0 0 0 0
Nexplanon 0 0 0 0
COCP 1 3.7 1 3.7
Depo-Provera 0 0 1 3.7
POP 0 0 2 7.4
Contraceptive ring 0 0 0 0
LNG-IUS 4 14.8 4 14.8
Other 1 3.7 1 3.7
Any used 5 18.5 7 25.9
COCP: combined oral contraceptive pill, POP: progesterone only contraceptive pill, LNG-IUS: levonorgestrel- releasing intrauterine system. Deep endometriosis is
defined as >5mm infiltration [22]
https://doi.org/10.1371/journal.pone.0227695.t001
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Acceptability of interventions
The acceptability of the interventions was evaluated by calculating the proportion of partici-
pants who attended all visits and completed their treatments: 82.4% (95% CI 56.6, 96.2%) of
participants (14/17) who received O-PUFA and 81.3% (95% CI 54.4, 96.0%) of participants
(13/16) who received olive oil capsules attended all visits. The majority of participants
described their overall trial experience favourably and rated it one or two on a five-point scale
from positive to negative. Positive responses were recorded for the recruitment approach used,
paperwork burden for participants and the experience of randomisation process of partici-
pants. Negative feedback was largely related to the size of the pills as some women experienced
discomfort when swallowing the large capsules, time taken to complete the treatment diary
and complexity of some of the questionnaires. The trial was not powered to detect difference
in outcomes recorded by questionnaires.
Adverse events
There was no report of any adverse event from any of the participant in either group.
Discussion
Our pilot trial demonstrates that a future definitive RCT to determine the efficacy of O-PUFA
for the treatment of women with endometriosis-associated pain is feasible. Feasibility is sup-
ported by the fact that, over a 12 month recruitment period, we were able to randomise 33
women (45.2% of those eligible) to O-PUFA or comparator and obtain completed eight week
follow up data in 27 women (81.8%).
A recent comprehensive review of the recruitment and retention data of a cohort of 151
RCTs funded and published by the UK NIHR HTA Programme from 2004 to 2016 found that
the average retention rate was 89% and the average proportion of eligible patients who are ran-
domised was 70% [23]. Whilst the retention rates in our pilot were less than the published
Fig 2. Example of sample size calculation for future definitive trial based on the BPI severity and interference
scores.
https://doi.org/10.1371/journal.pone.0227695.g002
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average retention rate of 89% (81.8%), we believe that this simply reflects the challenges of
working with a target population who have a chronic pain condition. We will therefore inflate
the sample size in our future RCT for to account for this level of attrition. The randomisation
rates were also less than the published average of 70% (45.2%) and marginally lower than we
had predicted (50%). These data are important and will allow us to estimate recruitment and
randomisation more accurately in our proposed future trial, and determine the number of
centres and the recruitment period that we will require. We are conscious that our trial had no
patient and public involvement (PPI) and aware of data on PPI in clinical trials that indicates
that PPI is likely to improve randomisation and retention of participants, especially if the PPI
group includes people with lived experience of the health condition under study [24]. We will
therefore ensure that we involve women with endometriosis and representatives from relevant
patient organisations in all aspects of our future trial, including the early stages of the trial pro-
posal and design.
We were pleased to note that analysis of the data regarding the delivery of the trial was gen-
erally favourable. The limited negative feedback that we received was largely related to trial
medication (large size of capsules) and treatment diary completion. Whilst the delivery of the
medication cannot be altered, the other feedback has alerted us to the need to develop the
option of a more accessible and user-friendly online treatment diary.
The observed trend toward improvement in pelvic pain and quality of life scores in both
treatment arms over the eight week intervention points to a strong placebo effect, which would
require a much larger sample size, or the use of much smaller (and likely clinically irrelevant)
effect sizes, to detect statistically significant differences between treatment groups. This sug-
gests an effect from enhanced clinical interaction and trial participation on pain, psychological
and physical well-being, and highlights a need for qualitative research to explore whether
women experience a placebo effect which influences their experiences and reporting of pain
and hence, potentially, trial outcomes. We are also aware that we used a potentially ‘active’ pla-
cebo. Olive oil contains oleocanthal which has been shown to act as a natural anti-inflamma-
tory compound that has a potency and profile strikingly similar to that of ibuprofen [25]. We
plan to use a more ‘inert’ substance as our placebo, that is unable to elicit an effect, our future
trial.
Conclusions
In conclusion, we are now ready to capitalise on our pilot trial and secure funding to perform
a definitive large multicentre double-blind randomised controlled trial to determine the effi-
cacy of O-PUFA for the treatment of women with endometriosis-associated pain.
Supporting information
S1 Consort checklist. CONSORT checklist for RCT protocols.
(DOC)
S1 Table. Results from secondary outcome measures–SF12. SF-12 version 2 scores range
from 0–100, where low scores are bad and high scores are good.
(DOCX)
S2 Table. Results from secondary outcome measures–BPI. BPI scores range from 0–10,
where low scores are good and high scores are bad.
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S6 Table. Results from secondary outcome measures–PCQ. 1 PCQ rumination scores range
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range from 0–24, where low scores are good and high scores are bad. 4 PCQ total scores range
from 0–52, where low scores are good and high scores are bad.
(DOCX)
S7 Table. Results from secondary outcome measures–SAQ. 1 SAQ pleasure scores range
from 0–18, where low scores are bad and high scores are good. 2 SAQ discomfort scores range
from 0–6, where low scores are bad and high scores are good. 3 SAQ habit scores range from
0–3, where low scores are bad and high scores are good. 4 SAQ tired scores range from 0–3,
where low scores are bad and high scores are good.
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S8 Table. Results from secondary outcome measures–PDQ. PDQ scores range from 0–35,
where low scores are good and high scores are bad.
(DOCX)
S1 Protocol.
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